Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Globe Newswire•01/10/2026•09:00 ET
0
Key Highlights
- ➤LXEO oral presentation accepted for MDS 2026, scheduled October 7 in Seoul
- ➤LX2006-treated participants showed early mFARS stabilization or improvement versus matched controls
- ➤New mFARS subscore analyses will provide additional insight into neurologic outcomes
- ➤LX2006 is being evaluated in SUNRISE-FA 2, a Phase 2 registrational trial
Expert Statements
Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics
“We are pleased to see LX2006 featured at MDS 2026 through an oral presentation by Dr. Zesiewicz. The presentation will continue to highlight the encouraging neurologic improvements observed in patients treated with LX2006, including new analyses of mFARS subscores, complementing the cardiac benefits reported to date. Together, these findings continue to build a compelling clinical profile for LX2006 and reinforce its potential to meaningfully address the multisystem burden of Friedreich ataxia.”
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study
Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment
Get started
Create a free account to read the full story.